Stimuvax failed to reach its primary endpoint.
http://www.reuters.com/article/2012/12/19/us-merck-stimuvax-idUSBRE8BI0CA20121219
Unfortunately for Prima, CVac shares the same MUC-1 target.
While it doesn't suggest that CVac could also fail, as the technologies of the two therapies are quite different, it certainly won't build confidence.
Might be a good idea for management to put any fears to rest before they rise.
